Table 4.

Phase II/III trials testing crenezumab.

Study Design and Duration	Study Population	Cognitive Primary Endpoint	CSF or Plasma Aβ	Amyloid PET	Volumetric MRI
Phase III, randomised, double-blind, placebo-controlled (CREAD, CREAD2) 100 weeks Terminated early [75]	Early AD	CDR-SB No significant effects	Significant increase in CSF and plasma	No significant effects	No significant effects
Phase II, randomised, double-blind, placebo-controlled (API ADAD Colombia) 5 to 8 years Terminated early [76,80,81]	Cognitively healthy Colombian family	APICC No significant effects	Stable levels/significant increase in CSF	No significant effects	No significant effects